SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Bovee Judith V.M.G.)
 

Sökning: WFRF:(Bovee Judith V.M.G.) > Zoledronic Acid Add...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006610naa a2200781 4500
001oai:lup.lub.lu.se:dc42c69e-a828-4c92-9d75-84f6a36d15f1
003SwePub
008240103s2023 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/dc42c69e-a828-4c92-9d75-84f6a36d15f12 URI
0247 a https://doi.org/10.1158/1078-0432.CCR-23-19662 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Koch, Raphaelu University of Münster4 aut
2451 0a Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
264 1c 2023
300 a 12 s.
520 a PURPOSE: The phase III, open-label, prospective, multicenter, randomized Ewing 2008R1 trial (EudraCT2008-003658-13) was conducted in 12 countries to evaluate the effect of zoledronic acid (ZOL) maintenance therapy compared with no add-on regarding event-free survival (EFS, primary endpoint) and overall survival (OS) in standard-risk Ewing sarcoma (EWS). PATIENTS AND METHODS: Eligible patients had localized EWS with either good histologic response to induction chemotherapy and/or small tumors (<200 mL). Patients received six cycles of VIDE induction and eight cycles of VAI (male) or eight cycles of VAC (female) consolidation. ZOL treatment started parallel to the sixth consolidation cycle. Randomization was stratified by tumor site (pelvis/other). The two-sided adaptive inverse-normal four-stage design (planned sample size 448 patients, significance level 5%, power 80%) was changed after the first interim analysis using the Müller-Schäfer method. RESULTS: Between April 2010 and November 2018, 284 patients were randomized (142 ZOL/142 no add-on). With a median follow-up of 3.9 years, EFS was not significantly different between ZOL and no add-on group in the adaptive design (HR, 0.74; 95% CI, 0.43-1.28, P = 0.27, intention-to-treat). Three-year EFS rates were 84.0% (95% CI, 77.7%-90.8%) for ZOL vs. 81.7% (95% CI, 75.2%-88.8%) for no add-on. Results were similar in the per-protocol collective. OS was not different between groups. The 3-year OS was 92.8% (95% CI, 88.4%-97.5%) for ZOL and 94.6% (95% CI, 90.9%-98.6%) for no add-on. Noticeable more renal, neurologic, and gastrointestinal toxicities were observed for ZOL (P < 0.05). Severe renal toxicities occurred more often in the ZOL arm (P = 0.003). CONCLUSIONS: In patients with standard-risk localized EWS, there is no additional benefit from maintenance treatment with ZOL.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Haveman, Lianneu Princess Maxima Center for Pediatric Oncology/Hematology4 aut
7001 a Ladenstein, Ruthu Medical University of Vienna4 aut
7001 a Brichard, Benedicteu Saint-Luc University Hospital4 aut
7001 a Jürgens, Heribertu University Hospital Münster4 aut
7001 a Cyprova, Sonau University Hospital Motol4 aut
7001 a van den Berg, Henku University of Amsterdam4 aut
7001 a Hassenpflug, Wolfu University Medical Center Hamburg-Eppendorf4 aut
7001 a Raciborska, Annau National Research Institute of Mother and Child4 aut
7001 a Ek, Torbenu Queen Silvia Children’s Hospital4 aut
7001 a Baumhoer, Danielu University Hospital Basel4 aut
7001 a Egerer, Gerlindeu University Hospital Heidelberg4 aut
7001 a Kager, Leou Medical University of Vienna4 aut
7001 a Renard, Marleenu University Hospitals Leuven4 aut
7001 a Hauser, Peter4 aut
7001 a Burdach, Stefanu Technical University of Munich4 aut
7001 a Bovee, Judith V.M.G.u Leiden University Medical Centre4 aut
7001 a Hong, Angela M.u University of Sydney4 aut
7001 a Reichardt, Peteru HELIOS Klinikum Berlin-Buch4 aut
7001 a Kruseova, Jarmilau University Hospital Motol4 aut
7001 a Streitbürger, Arneu University Hospital Essen4 aut
7001 a Kühne, Thomasu University Children's Hospital, Basel4 aut
7001 a Kessler, Torstenu University Hospital Münster4 aut
7001 a Bernkopf, Marieu Medical University of Vienna4 aut
7001 a Butterfaß-Bahloul, Trudeu University of Münster4 aut
7001 a Dhooge, Catharinau Ghent University Hospital4 aut
7001 a Bauer, Sebastianu University of Duisburg-Essen4 aut
7001 a Kiss, Jánosu Semmelweis University4 aut
7001 a Paulussen, Michaelu Witten/Herdecke University4 aut
7001 a Bonar, Fionau Royal Prince Alfred Hospital4 aut
7001 a Ranft, Andreasu German Cancer Research Centre,University Hospital Essen4 aut
7001 a Timmermann, Beateu University Hospital Essen,German Cancer Research Centre4 aut
7001 a Rascon, Jelenau Vilnius University4 aut
7001 a Vieth, Volker4 aut
7001 a Kanerva, Jukkau Helsinki University Central Hospital4 aut
7001 a Faldum, Andreasu University of Münster4 aut
7001 a Hartmann, Wolfgangu University Hospital Münster4 aut
7001 a Hjorth, Larsu Lund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Sena effekter efter barncancerbehandling,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Late effects after childhood cancer treatment,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital4 aut0 (Swepub:lu)pedi-lhj
7001 a Bhadri, Vivek A.u University of Sydney4 aut
7001 a Metzler, Markusu University Hospital Erlangen4 aut
7001 a Gelderblom, Hansu Leiden University Medical Centre4 aut
7001 a Dirksen, Utau German Cancer Research Centre,University Hospital Essen4 aut
7102 a University of Münsterb Princess Maxima Center for Pediatric Oncology/Hematology4 org
7730 t Clinical cancer research : an official journal of the American Association for Cancer Researchg 29:24, s. 5057-5068q 29:24<5057-5068x 1078-0432
8564 u http://dx.doi.org/10.1158/1078-0432.CCR-23-1966y FULLTEXT
8564 8u https://lup.lub.lu.se/record/dc42c69e-a828-4c92-9d75-84f6a36d15f1
8564 8u https://doi.org/10.1158/1078-0432.CCR-23-1966

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy